Wedbush Reaffirms “Outperform” Rating for Y-mAbs Therapeutics (NASDAQ:YMAB)
Y-mAbs Therapeutics (NASDAQ:YMAB – Get Free Report)‘s stock had its “outperform” rating reiterated by stock analysts at Wedbush in a research report issued to clients and investors on Wednesday, MarketBeat reports. They presently have a $18.00 price objective on the stock, down from their previous price objective of $21.00. Wedbush’s target price would suggest a […]
Y-mAbs Therapeutics (NASDAQ:YMAB – Get Free Report)‘s stock had its “outperform” rating reiterated by stock analysts at Wedbush in a research report issued to clients and investors on Wednesday, MarketBeat reports. They presently have a $18.00 price objective on the stock, down from their previous price objective of $21.00. Wedbush’s target price would suggest a […]
